Frontline Ltd. (FRO)
$
14.85
-0.12 (-0.81%)
Key metrics
Financial statements
Free cash flow per share
-0.8033
Market cap
3.3 Billion
Price to sales ratio
1.6254
Debt to equity
1.6004
Current ratio
1.3867
Income quality
1.4859
Average inventory
0
ROE
0.2088
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Frontline Ltd. is a global shipping company specializing in the seaborne transportation of crude oil and oil products. As of December 31, 2021, it operated a fleet of 70 vessels, further supported by its engagement in the charter, purchase, and sale of vessels. The operating expenses amount to $262,995,000.00 encompassing various operational costs incurred throughout its operations. The company reported an income before tax of $503,254,000.00 showcasing its pre-tax profitability, which underscores its efficient management of resources. Additionally, Frontline Ltd. incurred an interest expense of $0.00 reflecting its debt servicing obligations. The EBITDA ratio is 0.49 highlighting the company's operational efficiency and effectiveness in maintaining strong profit margins. Moreover, the gross profit stands at $1,044,708,000.00 demonstrating the company's profitability from its core operations and its ability to generate revenue. In the financial landscape, Frontline Ltd. presents an accessible investment opportunity as the stock is affordable at $14.67 making it suitable for budget-conscious investors. The stock has a high average trading volume of 3,470,191.00 indicating strong liquidity, which is essential for trading activities. With a mid-range market capitalization of $3,305,951,550.00 the company is a steady performer within the shipping sector. It is a key player in the Oil & Gas Midstream industry, contributing significantly to the overall market landscape and ensuring stability in volatile markets. Furthermore, it belongs to the Energy sector, driving innovation and growth while adapting to the changing dynamics of the shipping and logistics arena.
What is Frontline Ltd. (FRO)'s stock forecast?
Analysts predict Frontline Ltd. stock to fluctuate between $13.17 (low) and $29.39 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Frontline Ltd.'s market capitalization?
As of 2025-04-01, Frontline Ltd.'s market cap is $3,305,951,550, based on 222,623,000 outstanding shares.
How does Frontline Ltd. compare to competitors like GE Aerospace?
Compared to GE Aerospace, Frontline Ltd. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Frontline Ltd. (FRO) stock?
To buy Frontline Ltd. (FRO) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for FRO. Place an order (Market, Limit, etc.).
What is the best time to invest in Frontline Ltd.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Frontline Ltd. perform in the last earnings report?
Revenue: $2,050,385,000 | EPS: $2.23 | Growth: -24.41%.
Where can I find Frontline Ltd.'s investor relations reports?
Visit https://www.frontline.bm/investor-relations for detailed financial reports.
Where can I find historical stock prices for Frontline Ltd.?
You can explore historical data from here
What is the all-time high and low for Frontline Ltd. stock?
All-time high: $29.39 (2024-05-28) | All-time low: $5.73 (2021-01-29).
What are the key trends affecting Frontline Ltd. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
FRO, IX and UVSP made it to the Zacks Rank #1 (Strong Buy) income stocks list on April 1, 2025.
zacks.com
FRO, SAN and IX made it to the Zacks Rank #1 (Strong Buy) value stocks list on April 1, 2025.
zacks.com
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
prnewswire.com
Represents first ever triplet combination using targeted radiotherapy as a backbone therapy in AML with initial clinical data expected in 2H:2025 Expansion into frontline setting greatly expands potential addressable patient opportunity for Actimab-A Triplet combination supported by previously completed Phase 1 trials of Actimab-A + Venetoclax and Actimab-A + CLAG-M demonstrating Actimab-A's mutation agnostic and synergistic potential NEW YORK , March 11, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced that the first clinical trial under its previously announced Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) for Actimab-A has been initiated. The trial (NCT06802523) will evaluate the triplet combination comprised of Actimab-A, Venetoclax (Abbvie/Roche) an oral Bcl-2 inhibitor and ASTX-727 (Taiho Oncology, an Otsuka holdings company) a novel oral hypomethylating agent (HMA) in frontline acute myeloid leukemia (AML) patients.
marketbeat.com
Whether deserved or not, dividend stocks have a reputation for being somewhat boring—sturdy and dependable, but in low-growth industries or comprising companies that are well beyond their days of rapid share price gains. Though dividend stocks are not necessarily safe in all cases, they have a reputation for being a strong defensive play.
seekingalpha.com
Frontline Plc (NYSE:FRO ) Q4 2024 Earnings Conference Call February 28, 2025 9:00 AM ET Company Participants Lars Barstad - Chief Executive Officer Inger Klemp - Chief Financial Officer Conference Call Participants Jonathan Chappell - Evercore ISI Omar Nokta - Jefferies Sherif Elmaghrabi - BTIG Lars Barstad Thank you very much, dear all, and thank you for dialing into Frontline's quarterly earnings call. Being in the tanker industry, one is used to evolving and ever changing markets, largely affected by geopolitical events, but it's becoming a little bit exhausting having potential seismic shifts by the hour.
globenewswire.com
Aptose Announces Positive Clinical Safety Review and Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib
See all news
